Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Down 93.4% in January

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 8,100 shares, a decrease of 93.4% from the January 15th total of 123,100 shares. Based on an average daily volume of 371,000 shares, the short-interest ratio is currently 0.0 days.

Chugai Pharmaceutical Price Performance

OTCMKTS:CHGCY traded down $0.52 during trading hours on Wednesday, reaching $22.67. The company’s stock had a trading volume of 511,601 shares, compared to its average volume of 240,418. Chugai Pharmaceutical has a one year low of $14.52 and a one year high of $26.00. The business’s 50-day moving average is $21.77 and its 200-day moving average is $22.63. The company has a market cap of $74.61 billion, a price-to-earnings ratio of 29.44 and a beta of 0.81.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 22.16%. On average, sell-side analysts predict that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.